Furthermore, guilt-by-association results correlated lnckb.61426 to NOTCH3, a gene overexpressed in primary leukemia cells from high-risk patients [27], lnckb.32044 and lnckb.66409 to CFD, a complement regulatory gene linked to poor outcome in AML [28], and lnckb.66409 to PVR. The transmembrane glycoprotein encoded by PVR mediates cell adhesion, and was recently proposed as an epigenetic regulator for immunotherapy response in Multiple Myeloma [29]. This evidence concerns the gene CFD and plasma cell myeloma.